We developed a reliable system for the irradiation of xenografted tumors in mice which allows for accurate local irradiation under specific pathogen-free conditions. The system presented here consists of acrylic supports for mice and an acrylic box connected to a pump through 0.22 microns pore-sized filters. Mice with xenotransplanted tumors growing on their right hind legs were set on the supports and put into the box in a laminar flow hood. The tumors of 7 mice were irradiated simultaneously with X-rays of 6 and 10 MV generated by a linear accelerator at a dose rate of 3.1-4.7 Gy/min. The air was ventilated through filters during irradiation in the closed box. Microorganism tests confirmed that no bacteria entered or left the box. One of the significant characteristics of this setup is that it allows for irradiation under conditions of acute hypoxia, which is obtained using an integrated tourniquet. The dose variation among 7 tumors was less than 1%. The rest of the mouse's body was shielded effectively by a half-field technique and a lead block. As a result, the whole body dose for the mice was 0-4% of the total dose absorbed by the tumor. Due to the high dose rate and the ability to irradiate 7 mice simultaneously under specific pathogen-free conditions, this new system can be considered a time-saving and valuable tool for radiation oncology research.
en-copyright= kn-copyright= en-aut-name=KurodaMasahiro en-aut-sei=Kuroda en-aut-mei=Masahiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=InamuraKeiji en-aut-sei=Inamura en-aut-mei=Keiji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=TaharaSeiji en-aut-sei=Tahara en-aut-mei=Seiji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=KurabayashiYuzuru en-aut-sei=Kurabayashi en-aut-mei=Yuzuru kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=AkagiTadaatsu en-aut-sei=Akagi en-aut-mei=Tadaatsu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=AsaumiJunichi en-aut-sei=Asaumi en-aut-mei=Junichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=TogamiIzumi en-aut-sei=Togami en-aut-mei=Izumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=TakemotoMitsuhiro en-aut-sei=Takemoto en-aut-mei=Mitsuhiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=HondaOsamu en-aut-sei=Honda en-aut-mei=Osamu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=MoriokaYasuki en-aut-sei=Morioka en-aut-mei=Yasuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Okayama University affil-num=9 en-affil= kn-affil=Okayama University affil-num=10 en-affil= kn-affil=Okayama University affil-num=11 en-affil= kn-affil=Okayama University affil-num=12 en-affil= kn-affil=Okayama University en-keyword=animal experiment kn-keyword=animal experiment en-keyword=mouse kn-keyword=mouse en-keyword=radiotherapy kn-keyword=radiotherapy en-keyword=linear accelerator kn-keyword=linear accelerator en-keyword=specirfic pathogen-free kn-keyword=specirfic pathogen-free END start-ver=1.4 cd-journal=joma no-vol=47 cd-vols= no-issue=3 article-no= start-page=169 end-page=174 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=199306 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Hyperthermotherapy added to the multidisciplinary therapy for penile cancer. en-subtitle= kn-subtitle= en-abstract= kn-abstract=We performed a long-term follow-up of 4 patients with penile cancer who underwent hyperthermotherapy from August 1985 until August 1992. Hyperthermia was applied using a frequency of 350 MHz with a waveguide applicator twice a week for 60 min each for an average of 9.5 times (varying from 6 to 13 times). The total heating time that the temperature of urethra could be kept above 42 degrees C, was 166 min on the average (ranging from 0 to 463 min). Two patients classified as stage I according to the Jackson classification and 1 patient classified as stage IV underwent combined radiotherapy and received an average radiation dose of 53 Gy (range, 40-70 Gy). Among these patients 2 underwent combined chemotherapy with bleomycin or peplomycin. Malignant cells disappeared posttherapeutically and in August 1992, after an average of 5 years and 9 months (varying from 4 years 6 months to 6 years 10 months), the patients were free of recurrences. The one patient on stage IV had extensive invasion of the abdominal wall, but still recovered completely. One patient on stage III underwent combined chemotherapy and hyperthermotherapy, but heating had obviously been insufficient. There was a residue of malignant cells after the treatment and we performed a penectomy. Regarding functional preservation of the penis a multidisciplinary therapy incorporating hyperthermotherapy can be expected to increase the curativity. This indicates that it could induce in an advanced case, where an operation would be difficult, complete remission.
en-copyright= kn-copyright= en-aut-name=KurodaMasahiro en-aut-sei=Kuroda en-aut-mei=Masahiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=TsushimaTomoyasu en-aut-sei=Tsushima en-aut-mei=Tomoyasu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=NasuYasutomo en-aut-sei=Nasu en-aut-mei=Yasutomo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=AsaumiJunichi en-aut-sei=Asaumi en-aut-mei=Junichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=NishikawaKoji en-aut-sei=Nishikawa en-aut-mei=Koji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=GaoXian Shu en-aut-sei=Gao en-aut-mei=Xian Shu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=JojaIkuo en-aut-sei=Joja en-aut-mei=Ikuo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=TakedaYoshihiro en-aut-sei=Takeda en-aut-mei=Yoshihiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=TogamiIzumi en-aut-sei=Togami en-aut-mei=Izumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=MakihataEiichi en-aut-sei=Makihata en-aut-mei=Eiichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=OhmoriHiroyuki en-aut-sei=Ohmori en-aut-mei=Hiroyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Okayama Univresity affil-num=9 en-affil= kn-affil=Okayama University affil-num=10 en-affil= kn-affil=Okayama University affil-num=11 en-affil= kn-affil=Okayama University affil-num=12 en-affil= kn-affil=Okayama University affil-num=13 en-affil= kn-affil=Okayama University en-keyword=penile cancer kn-keyword=penile cancer en-keyword=hyperthermia kn-keyword=hyperthermia en-keyword=radiotherapy kn-keyword=radiotherapy en-keyword=chemotherapy kn-keyword=chemotherapy END start-ver=1.4 cd-journal=joma no-vol=47 cd-vols= no-issue=4 article-no= start-page=249 end-page=254 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=199308 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Hyperthermotherapy for postoperative local recurrences of rectal cancer. en-subtitle= kn-subtitle= en-abstract= kn-abstract=Between November 1984 and August 1992 we used hyperthermotherapy in six cases of local recurrence of rectal cancer. Hyperthermotherapy was performed on the average 8.7 times (range: 3-18) for each patient for 60 min each. All patients underwent combined radiotherapy and received a mean radiation dose of 42.5 Gy (range: 9-60 Gy). Five patients underwent heating within 1 h after irradiation and one patient simultaneously with the irradiation. Four patients underwent combined chemotherapy and two patients immunotherapy. Before the treatment all patients had painful lesions, but pain decreased posttherapeutically in five patients. Performance status improved in two patients. High carcinoembryonic antigen levels prior to the therapy in four patients decreased in all cases after treatment. Posttherapeutical computed tomograms revealed only minor response or no changes. After the treatment, four patients died of exacerbations of recurrent tumors and one patient of distant metastases. The patient who underwent simultaneous radiohyperthermotherapy is presently alive, in August 1992, 38 months after initiation of the treatment. The 50% survival time after initiation of the treatment was 25 months (range: 10-38 months). Hyperthermotherapy combined with radiotherapy, chemotherapy and/or immunotherapy was useful for the alleviation of pain in patients who developed local recurrence after surgery, and improved survival after recurrences can be expected.
en-copyright= kn-copyright= en-aut-name=KurodaMasahiro en-aut-sei=Kuroda en-aut-mei=Masahiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=HizutaAkio en-aut-sei=Hizuta en-aut-mei=Akio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=IwagakiHiromi en-aut-sei=Iwagaki en-aut-mei=Hiromi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=MakihataEiichi en-aut-sei=Makihata en-aut-mei=Eiichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=AsaumiJunichi en-aut-sei=Asaumi en-aut-mei=Junichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=NishikawaKoji en-aut-sei=Nishikawa en-aut-mei=Koji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=GaoXian Shu en-aut-sei=Gao en-aut-mei=Xian Shu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=NakagawaTomio en-aut-sei=Nakagawa en-aut-mei=Tomio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=TogamiIzumi en-aut-sei=Togami en-aut-mei=Izumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=TakedaYoshihiro en-aut-sei=Takeda en-aut-mei=Yoshihiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=JojaIkuo en-aut-sei=Joja en-aut-mei=Ikuo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=OritaKunzo en-aut-sei=Orita en-aut-mei=Kunzo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=14 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Okayama University affil-num=9 en-affil= kn-affil=Okayama University affil-num=10 en-affil= kn-affil=Okayama University affil-num=11 en-affil= kn-affil=Okayama University affil-num=12 en-affil= kn-affil=Okayama University affil-num=13 en-affil= kn-affil=Okayama University affil-num=14 en-affil= kn-affil=Okayama University en-keyword=rectal cancer kn-keyword=rectal cancer en-keyword=local recurrence kn-keyword=local recurrence en-keyword=hyperthermia kn-keyword=hyperthermia en-keyword=radiotherapy kn-keyword=radiotherapy en-keyword=chemotherapy kn-keyword=chemotherapy END start-ver=1.4 cd-journal=joma no-vol=62 cd-vols= no-issue=1 article-no= start-page=37 end-page=44 dt-received= dt-revised= dt-accepted= dt-pub-year=2008 dt-pub=200802 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Phase I Trial of Escalating-dose Cisplatin with 5-fluorouracil and Concurrent Radiotherapy in Chinese Patients with Esophageal Cancer en-subtitle= kn-subtitle= en-abstract= kn-abstract=We defined the maximum-tolerated dose (MTD) of chemoradiotherapy (cisplatin (CDDP) with 5-fluorouracil (5-FU) and concurrent chemoradiotherapy) for Chinese patients with esophageal cancer. Twenty-one previously untreated patients with primary esophageal cancer were entered into this study. Escalating doses of CDDP with 5-FU were administered in a modified Fibonacci sequence, with concurrent conventional fractionation radiotherapy (CFR) of 60 Gy or 50 Gy. The starting doses were CDDP 37.5 mg/m2 on day 1, and 5-FU 500 mg/m2 on days 1-5, respectively. The regimen was repeated 4 times every 28 days. If no dose-limiting toxicity (DLT) was observed, the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was declared to be 1 dose level below the level at which DLT appeared. DLT was grade 3 radiation-induced esophagitis at a dose level of CDDP 60 mg/m2 with 5-FU 700 mg/m2 and concurrent 60 Gy CFR. MTD was defined as CDDP 52.5 mg/m2 with 5-FU 700 mg/m2 and concurrent 50 Gy CFR. The MTD of CDDP with 5-FU and in concurrent chemoradiotherapy for Chinese patients with esophageal cancer is CDDP 52.5 mg/m2 on day 1 and 5FU 700 mg/m2 on days 1-5, repeated 4 times every 28 days, and concurrent 50 Gy CFR. Further evaluation of this regimen in a prospective phase II trial is ongoing.
en-copyright= kn-copyright= en-aut-name=LinQiang en-aut-sei=Lin en-aut-mei=Qiang kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=GaoXian-Shu en-aut-sei=Gao en-aut-mei=Xian-Shu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=QiaoXue-Ying en-aut-sei=Qiao en-aut-mei=Xue-Ying kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=ZhouZhi-Guo en-aut-sei=Zhou en-aut-mei=Zhi-Guo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=ZhangPing en-aut-sei=Zhang en-aut-mei=Ping kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=ChenKun en-aut-sei=Chen en-aut-mei=Kun kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=ZhaoYan-Nan en-aut-sei=Zhao en-aut-mei=Yan-Nan kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=AsaumiJunichi en-aut-sei=Asaumi en-aut-mei=Junichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= affil-num=1 en-affil= kn-affil=Hebei Medical University Fourth Hospital affil-num=2 en-affil= kn-affil=Hebei Medical University Fourth Hospital affil-num=3 en-affil= kn-affil=Hebei Medical University Fourth Hospital affil-num=4 en-affil= kn-affil=Hebei Medical University Fourth Hospital affil-num=5 en-affil= kn-affil=Hebei Medical University Fourth Hospital affil-num=6 en-affil= kn-affil=North China Petroleum Bureau General Hospital affil-num=7 en-affil= kn-affil=North China Petroleum Bureau General Hospital affil-num=8 en-affil= kn-affil=Okayama University en-keyword=esophageal neoplasm kn-keyword=esophageal neoplasm en-keyword=concurrent chemoradiotherapy kn-keyword=concurrent chemoradiotherapy en-keyword=cisplatin kn-keyword=cisplatin en-keyword=5-fluorouracil kn-keyword=5-fluorouracil en-keyword=dose escalation kn-keyword=dose escalation END start-ver=1.4 cd-journal=joma no-vol=51 cd-vols= no-issue=2 article-no= start-page=93 end-page=99 dt-received= dt-revised= dt-accepted= dt-pub-year=1997 dt-pub=199704 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Preoperative multidisciplinary treatment with hyperthermia for soft tissue sarcoma en-subtitle= kn-subtitle= en-abstract= kn-abstract=We report the results of phase I/II studies of preoperative multidisciplinary treatment of 14 patients with soft tissue sarcoma using hyperthermia from November 1990 to April 1995. The preoperative treatment was conducted with thermo-radio-chemotherapy in 11 cases of stage III, and with thermo-radiotherapy as well as thermo-chemotherapy in three cases of stages I and II. Hyperthermia was carried out twice a week with totals ranging from 4 to 14 times (average: 8.4 times); each session lasted 60min. Radiotherapy was administered four or five times per week, and the dose was 1.8 2Gy/fraction, with a total of 30-40Gy in a four week period. Chemotherapy was mainly in the form of MAID regimen (2-mercaptoethanesulphonic acid (mesna), adriamycin, ifosfamide and dacarbazine). The tumors were surgically resected in all patients after completing the preoperative treatment. The efficacy rate, as expressed by the percentage of either tumors in which reduction rate was 50% or more, or tumors for which post-treatment contrast enhanced CT image revealed low density volumes occupying 50% or more of the total mass, was 71 % (ten of the 14 tumors). The mean tumor necrosis rate in the resected specimens was 78%. The tumor necrosis rate was significantly high (P < 0.05) in patients whose Time ≥ 42°C was of long duration. Postoperative complications were observed in six patients; among these, two patients developed wound infection that required surgical treatment as a complication of surgery performed in the early stage following the preoperative treatment. After a mean postoperative follow-up of 27 months, distant metastasis occurred in four patients resulting in three fatalities. The three-year cumulative survival rate was 64.3%. No local recurrence was observed in any patient during the follow-up, thus confirming our hypothesis that preoperative multidisciplinary treatment has an excellent local efficacy. We think that it would be valuable to conduct, at many facilities, phase III studies on the treatment of soft tissue sarcoma by a combination of surgery and preoperative multidisciplinary treatment using hyperthermia, paying close attention to the interval between these two modalities.
en-copyright= kn-copyright= en-aut-name=MakihataEiichi en-aut-sei=Makihata en-aut-mei=Eiichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=KurodaMasahiro en-aut-sei=Kuroda en-aut-mei=Masahiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KawaiAkira en-aut-sei=Kawai en-aut-mei=Akira kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=OzakiToshifumi en-aut-sei=Ozaki en-aut-mei=Toshifumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=SugiharaShinsuke en-aut-sei=Sugihara en-aut-mei=Shinsuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=InoueHajime en-aut-sei=Inoue en-aut-mei=Hajime kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=JojaIkuo en-aut-sei=Joja en-aut-mei=Ikuo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=AsaumiJunichi en-aut-sei=Asaumi en-aut-mei=Junichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Okayama University affil-num=9 en-affil= kn-affil=Okayama University affil-num=10 en-affil= kn-affil=Okayama University en-keyword=soft tissue tumor kn-keyword=soft tissue tumor en-keyword=hyperthermia kn-keyword=hyperthermia en-keyword=radiotherapy kn-keyword=radiotherapy en-keyword=chemotherapy kn-keyword=chemotherapy END start-ver=1.4 cd-journal=joma no-vol=9 cd-vols= no-issue=2 article-no= start-page=75 end-page=81 dt-received= dt-revised= dt-accepted= dt-pub-year=1999 dt-pub=19990226 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Relative biological effectiveness (RBE) and potential leathal damage repair (PLDR) of heavy-ion beam kn-title=重粒子線の生物学的効果比と潜在性致死損傷からの回復 en-subtitle= kn-subtitle= en-abstract=Relative biological effectiveness (RBE) and repair of potential lethal damage (PLDR) of NIH3T3 cells against heavy-ion radiation were studied. RBE of 150 KV X-rays and neutron estimated from LD(10) dose of dose response survival curves compared to (60)Co γ-ray were 1.26 and 2.44, respectively. RBE of 13, 20, 50, 90, 140, 150, 153, 200 keV/μm of LET of carbon beam were 1.41, 1.47, 2.22, 2.61, 2.61, 1.61, 2.05 and 1.57, respectively. Potential lethal damage repair (PLDR) after exposure to carbon beam was observed. The magnitude of PLDR of (60)Co γ-ray was the biggest. As for the carbon beam of LET of 13 keV/μm as well, PLDR were observed. PLDR decreased when LET of carbon beam grew big. kn-abstract=150KV X線,中性子線及び炭素(LET13, 20, 50, 90, 140, 150, 153, 200keV/μm)を照射したマウスNIH3T3細胞の生存率曲線のLD(10)から(60)Coγ線に対する生物学的効果比(RBE)を求めた｡RBEは150KV X線では1.26,中性子線では2.44,炭素線(LET13, 20, 50, 90, 140, 150, 153, 200keV/μm)ではそれぞれ1.41, 1.47, 2.22, 2.61, 1.61, 2.05, 1.57であった｡LETとRBEの関係では100keV/μm付近にピークを認めた｡150KVX線のLETは13keV/μm,中性子線のLETは70keVμmに相当した｡(60)Co γ線の潜在性致死損傷からの回復(PLDR)は大きかった｡炭素線(13keV/μm)照射でもPLDRが観察されるがLETが大きくなるとPLDRは減少したが,LET90keV/μmの炭素線でもPLDRが認められた｡照射時の細胞状態の検討では増殖期の細胞の感受性は定常期細胞に比し僅かに高かった｡ en-copyright= kn-copyright= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name=川崎祥二 kn-aut-sei=川崎 kn-aut-mei=祥二 aut-affil-num=1 ORCID= en-aut-name=ShibuyaKoichi en-aut-sei=Shibuya en-aut-mei=Koichi kn-aut-name=澁谷光一 kn-aut-sei=澁谷 kn-aut-mei=光一 aut-affil-num=2 ORCID= en-aut-name=AsaumiJunichi en-aut-sei=Asaumi en-aut-mei=Junichi kn-aut-name=浅海淳一 kn-aut-sei=浅海 kn-aut-mei=淳一 aut-affil-num=3 ORCID= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=小松めぐみ kn-aut-sei=小松 kn-aut-mei=めぐみ aut-affil-num=4 ORCID= en-aut-name=KurodaMasahiro en-aut-sei=Kuroda en-aut-mei=Masahiro kn-aut-name=黒田昌宏 kn-aut-sei=黒田 kn-aut-mei=昌宏 aut-affil-num=5 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name=平木祥夫 kn-aut-sei=平木 kn-aut-mei=祥夫 aut-affil-num=6 ORCID= en-aut-name=FurusawaYoshiya en-aut-sei=Furusawa en-aut-mei=Yoshiya kn-aut-name=古澤佳也 kn-aut-sei=古澤 kn-aut-mei=佳也 aut-affil-num=7 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部保健学科放射線技術科学専攻 affil-num=2 en-affil= kn-affil=岡山大学医学部保健学科放射線技術科学専攻 affil-num=3 en-affil= kn-affil=岡山大学歯学部歯科放射線学講座 affil-num=4 en-affil= kn-affil=岡山大学医学部医学科放射線医学講座 affil-num=5 en-affil= kn-affil=岡山大学医学部医学科放射線医学講座 affil-num=6 en-affil= kn-affil=岡山大学医学部医学科放射線医学講座 affil-num=7 en-affil= kn-affil=放射線医学研究所宇宙粒子線研究グループ en-keyword=PLDR kn-keyword=PLDR en-keyword=RBE kn-keyword=RBE en-keyword=Heavy-lon Radiation kn-keyword=Heavy-lon Radiation en-keyword=NIH3T3 Cells kn-keyword=NIH3T3 Cells END start-ver=1.4 cd-journal=joma no-vol=12 cd-vols= no-issue=2 article-no= start-page=101 end-page=106 dt-received= dt-revised= dt-accepted= dt-pub-year=2002 dt-pub=20020320 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=加温後のtsAF8細胞の細胞周期 kn-title=Cell cycle of tsAF8 after heating en-subtitle= kn-subtitle= en-abstract=tsAF8細胞は45℃の加温後34℃で培養すると温熱耐性が速やかに発現するが,加温後,制限温度である39.7℃で培養すると温熱耐性の発現が抑制される｡加温後の培養温度が細胞周期に影響し,その結果として温熱耐性発現に影響を与えている可能性があることから,今回,Propidium Iodide(PI)とbromodeoxyuridine(BrdU)でtsAF8細胞を二重染色し,フローサイトメトリーによって温熱耐性と細胞周期の関係の有無について調べた｡tsAF8細胞を45℃20分の加温後34℃で培養すると,6時間後にはG(1)期の細胞が減少し,12時間後にはG(2)/M期への蓄積が見られた｡しかし,加温後39.7℃で培養した場合には細胞周期の進行がほとんど見られなかった｡BrdU の取込みは,加温せずに39.7℃で培養した場合には活発に行われ,また,45℃20分加温後34℃で培養した場合には,6時間後にはBrdUの取り込みは65.1%まで回復した｡しかし,温熱耐性発現の抑制が観察される45℃20分加温後39.7℃で培養した場合には,BrdUの取込み量は6時間後に一時的に15.1%に回復するが,12時間後には取込み量はゼロとなった｡BrdUの取り込みが阻害されたのはstep-down heatingの現象による細胞生存率の減少が原因だと考えられたが,温熱耐性発現の抑制が観察される条件下では細胞周期の特定の時期への集積がなかったことから,温熱耐性と細胞周期との関係はtsAF8細胞においては見い出されなかった｡ kn-abstract=Thermotolerance in tsAF8 cells develops during incubation at 34℃ after heating at 45℃, while it is suppressed by the following incubation at a non-permissive temperature of 39.7℃ after the same heating. The incubation temperature after heating may affect the cell cycle and consequently thermotolerance. In the present study, a relationship between the thermotolerance and the cell cycle of tsAF8 was investigated. The cell cycle fractions and DNA synthesis were measured by flow cytometry using double staining with propidium iodide and bromodeoxyuridine. When the tsAF8 cells were heated at 45℃ for 20 min, and thereafter incubated at 34℃, bromodeoxyuridine uptake in the S phase cells (DNA synthesis) was recovered to 65.1% 6 h after the heating, and the cells showed gradual accumulation in the G(2)/M phase. When the cells were incubated at 39.7℃ after heating at 45℃ for 20 min, then showed inhibition of thermotolerance development, the DNA synthesis was recovered to 15.1% temporarily 6 h after the heating, but it became 0% after 12 h, and the cells did not remarkably accumulate in any phases of the cell cycle. This inhibition of DNA synthesis at 39.7℃ was considered to be the result of cell survival decreasing by a step-down heating. However, the relationship between the thermotolerance and the cell cycle was not found out in tsAF8 cells, because the cells did not accumulate in any phases of the cell cycle under the inhibitory condition of thermotolerance. en-copyright= kn-copyright= en-aut-name=ShibuyaKoichi en-aut-sei=Shibuya en-aut-mei=Koichi kn-aut-name=澁谷光一 kn-aut-sei=澁谷 kn-aut-mei=光一 aut-affil-num=1 ORCID= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name=川崎祥二 kn-aut-sei=川崎 kn-aut-mei=祥二 aut-affil-num=2 ORCID= en-aut-name=KurodaMasahiro en-aut-sei=Kuroda en-aut-mei=Masahiro kn-aut-name=黒田昌宏 kn-aut-sei=黒田 kn-aut-mei=昌宏 aut-affil-num=3 ORCID= en-aut-name=AsaumiJun-ichi en-aut-sei=Asaumi en-aut-mei=Jun-ichi kn-aut-name=浅海淳一 kn-aut-sei=浅海 kn-aut-mei=淳一 aut-affil-num=4 ORCID= en-aut-name=KatoHirokazu en-aut-sei=Kato en-aut-mei=Hirokazu kn-aut-name=加藤博和 kn-aut-sei=加藤 kn-aut-mei=博和 aut-affil-num=5 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name=平木祥夫 kn-aut-sei=平木 kn-aut-mei=祥夫 aut-affil-num=6 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部保健学科放射線技術科学専攻 affil-num=2 en-affil= kn-affil=岡山大学医学部保健学科放射線技術科学専攻 affil-num=3 en-affil= kn-affil=岡山大学医学部附属病院放射線科 affil-num=4 en-affil= kn-affil=岡山大学歯学部附属病院歯科放射線科 affil-num=5 en-affil= kn-affil=岡山大学医学部保健学科放射線技術科学専攻 affil-num=6 en-affil= kn-affil=岡山大学医学部附属病院放射線科 en-keyword=thermotolerance (温熱耐性) kn-keyword=thermotolerance (温熱耐性) en-keyword=hyperthermia (ハイパーサーミア) kn-keyword=hyperthermia (ハイパーサーミア) en-keyword=tsAF8 kn-keyword=tsAF8 en-keyword=cell cycle (細胞周期) kn-keyword=cell cycle (細胞周期) END start-ver=1.4 cd-journal=joma no-vol=105 cd-vols= no-issue=1-2 article-no= start-page=43 end-page=48 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=199302 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Thermotolerance induction by benzalkonium chloride in NIH3T3 cells kn-title=塩化ベンザルコニウムによる温熱耐性の誘導 en-subtitle= kn-subtitle= en-abstract= kn-abstract=The ability of benzalkonium chloride to induce thermotolerance was examined in NIH3T3 cells. Benzalkonium chloride enhanced cytotoxicity as its concentration and administration period increased. The cell survival decreased to 50% of that in the non-treated group by 20min of treatment in 0.002% benzalkonium chloride. Thermotolerance developed during the culture after 20min of treatment with 0.002% benzalkonium chloride. Thermotolerance reached its peak at 15h after treatment and decreased subsequently. At 15h after treatment, the Do value at 45℃ heating, a parameter of thermotolerance was 3.8-fold higher than that of the non-treated group. The thermotolerance induced by 0.002% benzalkonium chloride increased as its treatment period was prolonged. These findings suggested a relationship between thermotolerance induction and the cell membrane damage by benzalkonium chloride. en-copyright= kn-copyright= en-aut-name=KurodaMasahiro en-aut-sei=Kuroda en-aut-mei=Masahiro kn-aut-name=黒田昌宏 kn-aut-sei=黒田 kn-aut-mei=昌宏 aut-affil-num=1 ORCID= en-aut-name=AsaumiJunichi en-aut-sei=Asaumi en-aut-mei=Junichi kn-aut-name=浅海淳一 kn-aut-sei=浅海 kn-aut-mei=淳一 aut-affil-num=2 ORCID= en-aut-name=NishikawaKoji en-aut-sei=Nishikawa en-aut-mei=Koji kn-aut-name=西川光治 kn-aut-sei=西川 kn-aut-mei=光治 aut-affil-num=3 ORCID= en-aut-name=TanakaSeiryo en-aut-sei=Tanaka en-aut-mei=Seiryo kn-aut-name=田中聖了 kn-aut-sei=田中 kn-aut-mei=聖了 aut-affil-num=4 ORCID= en-aut-name=GaoXian Shu en-aut-sei=Gao en-aut-mei=Xian Shu kn-aut-name=高献書 kn-aut-sei=高 kn-aut-mei=献書 aut-affil-num=5 ORCID= en-aut-name=YamamotoMichinori en-aut-sei=Yamamoto en-aut-mei=Michinori kn-aut-name=山本道法 kn-aut-sei=山本 kn-aut-mei=道法 aut-affil-num=6 ORCID= en-aut-name=MakihataEiichi en-aut-sei=Makihata en-aut-mei=Eiichi kn-aut-name=巻幡栄一 kn-aut-sei=巻幡 kn-aut-mei=栄一 aut-affil-num=7 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name=平木祥夫 kn-aut-sei=平木 kn-aut-mei=祥夫 aut-affil-num=8 ORCID= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name=川崎祥二 kn-aut-sei=川崎 kn-aut-mei=祥二 aut-affil-num=9 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=2 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=3 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=4 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=5 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=6 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=7 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=8 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=9 en-affil= kn-affil=岡山大学医療技術短期大学部診療放射線技術学科 en-keyword=温熱療法 kn-keyword=温熱療法 en-keyword=温熱耐性 kn-keyword=温熱耐性 en-keyword=塩化ベンザルコニウム kn-keyword=塩化ベンザルコニウム END start-ver=1.4 cd-journal=joma no-vol=5 cd-vols= no-issue= article-no= start-page=95 end-page=98 dt-received= dt-revised= dt-accepted= dt-pub-year=1995 dt-pub=19950131 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Oyygen uptake of adriamycin resistant cells of Ehrlich ascites tumor kn-title=アドリアマイシン耐性細胞の酸素呼吸 en-subtitle= kn-subtitle= en-abstract=Adriamycin-resistant cells of Ehrlich ascites tumor cells were established in our laboratory. Using electron microscope, the area of mitochondria (MT) per cytoplasm of ADR-resistant cells were measured with planimeter. The values of wild-type cells, 1μg/ml ADR-resistant cells and 10μg/ml ADR-resistant cells were 39.3, 51.8 and 57.7 μ(2) per 1,000 μ(2) of cytoplasm, respectively. Oxygen consumption of 1 μg/ml ADR-resistant cells and 10 μg/ml ADR-resistant cells were 1.45-fold and 1.49-fold compared to that of wild-type cells, respectively. These results indicate that ADR-resistant cells require more energy to work efflux pump than wild-type cells. kn-abstract=エールリッヒ腹水癌細胞を用いアドリアマイシンに対する耐性細胞（ADR耐性細胞）を樹立した。電子顕微鏡を用い撮影写真から細胞質当たりのミトコンドリア（MT）の割合を面積比で求めた。親株に比較して1μg/ml ADR耐性細胞では1.32倍、10μg/ml ADR耐性細胞では1.47倍であった。これらの細胞の呼吸を測定した。耐性細胞の内発呼吸は親株に比較して増加していた。1μg/ml ADR耐性細胞では1.45倍、10μg/ml ADR耐性細胞では1.49倍であり、MTの増加量とほぼ同じ割合であった。これらのことから、細胞が耐性になるとエネルギー消費が高まるために細胞内MTが増加し、その結果呼吸（酸素消費）が増加することが推察された。 en-copyright= kn-copyright= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name=川ｱ祥二 kn-aut-sei=川ｱ kn-aut-mei=祥二 aut-affil-num=1 ORCID= en-aut-name=NomuraTakako en-aut-sei=Nomura en-aut-mei=Takako kn-aut-name=野村貴子 kn-aut-sei=野村 kn-aut-mei=貴子 aut-affil-num=2 ORCID= en-aut-name=MatsuuraJunko en-aut-sei=Matsuura en-aut-mei=Junko kn-aut-name=松浦順子 kn-aut-sei=松浦 kn-aut-mei=順子 aut-affil-num=3 ORCID= en-aut-name=SasakiJunzo en-aut-sei=Sasaki en-aut-mei=Junzo kn-aut-name=佐々木順造 kn-aut-sei=佐々木 kn-aut-mei=順造 aut-affil-num=4 ORCID= en-aut-name=GaoXian Shu en-aut-sei=Gao en-aut-mei=Xian Shu kn-aut-name=高献書 kn-aut-sei=高 kn-aut-mei=献書 aut-affil-num=5 ORCID= en-aut-name=AsaumiJun-ichi en-aut-sei=Asaumi en-aut-mei=Jun-ichi kn-aut-name=浅海淳一 kn-aut-sei=浅海 kn-aut-mei=淳一 aut-affil-num=6 ORCID= en-aut-name=Nishikawakouji en-aut-sei=Nishikawa en-aut-mei=kouji kn-aut-name=西川光治 kn-aut-sei=西川 kn-aut-mei=光治 aut-affil-num=7 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name=平木祥夫 kn-aut-sei=平木 kn-aut-mei=祥夫 aut-affil-num=8 ORCID= en-aut-name=UtsumiKozo en-aut-sei=Utsumi en-aut-mei=Kozo kn-aut-name=内海耕慥 kn-aut-sei=内海 kn-aut-mei=耕慥 aut-affil-num=9 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医療技術短期大学部診療放射線技術学科 affil-num=2 en-affil= kn-affil=岡山大学医学部第1解剖学教室 affil-num=3 en-affil= kn-affil=岡山大学医学部第1解剖学教室 affil-num=4 en-affil= kn-affil=岡山大学医学部第1解剖学教室 affil-num=5 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=6 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=7 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=8 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=9 en-affil= kn-affil=倉敷成人病センター en-keyword=アドリアマイシン (adriamycin) kn-keyword=アドリアマイシン (adriamycin) en-keyword=多剤耐性 (multidrugs resistant) kn-keyword=多剤耐性 (multidrugs resistant) en-keyword=酸素消費 (oxygen uptake) kn-keyword=酸素消費 (oxygen uptake) en-keyword=呼吸 (respiration) kn-keyword=呼吸 (respiration) en-keyword=ミトコンドリア (mitochondria) kn-keyword=ミトコンドリア (mitochondria) END start-ver=1.4 cd-journal=joma no-vol=3 cd-vols= no-issue= article-no= start-page=81 end-page=85 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=19930131 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Relationship between intracellular uptake of adriamycin and membrane potential in ADR resistant Ehrlich ascites tumor cells kn-title=薬剤耐性細胞におけるアドリアマイシンの細胞内取り込みと細胞膜電位差の相関 en-subtitle= kn-subtitle= en-abstract= kn-abstract=We observed adiamycin (ADR) uptake and cellular transmembrane potential [amount of intracellular fluorescence of 3,3'- (Di-n-hexyl)- 2,2'- oxacarbocyanine iodide (NK-2280)] in ADR-resistant cells established from Ehrlich ascites tumor cells (EATC) and wild type EATC. In ADR-resistant cells, ADR uptake and the cellular transmembrane potential decreased as the degree of resistance increased. 4,4'- diisothiocyanatostilbene- 2,2'- disulfonic acid (DIDS) induced markedly decreases of ADR uptake and the cellular transmembrane potential. A good correlation was observed between ADR uptake and transmembrane potential in cultured cells. en-copyright= kn-copyright= en-aut-name=AsaumiJun-ichi en-aut-sei=Asaumi en-aut-mei=Jun-ichi kn-aut-name=浅海淳一 kn-aut-sei=浅海 kn-aut-mei=淳一 aut-affil-num=1 ORCID= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name=川崎祥二 kn-aut-sei=川崎 kn-aut-mei=祥二 aut-affil-num=2 ORCID= en-aut-name=NishikawaKoji en-aut-sei=Nishikawa en-aut-mei=Koji kn-aut-name=西川光治 kn-aut-sei=西川 kn-aut-mei=光治 aut-affil-num=3 ORCID= en-aut-name=Shu GaoXian en-aut-sei=Shu Gao en-aut-mei=Xian kn-aut-name=高献書 kn-aut-sei=高献 kn-aut-mei=書 aut-affil-num=4 ORCID= en-aut-name=KurodaMasahiro en-aut-sei=Kuroda en-aut-mei=Masahiro kn-aut-name=黒田昌宏 kn-aut-sei=黒田 kn-aut-mei=昌宏 aut-affil-num=5 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name=平木祥夫 kn-aut-sei=平木 kn-aut-mei=祥夫 aut-affil-num=6 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=2 en-affil= kn-affil=岡山大学医療技術短期大学部診療放射線技術学科 affil-num=3 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=4 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=5 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=6 en-affil= kn-affil=岡山大学医学部放射線医学教室 en-keyword=Adriamycin kn-keyword=Adriamycin en-keyword=Cell Membrane Potential kn-keyword=Cell Membrane Potential en-keyword=Flow Cytometry kn-keyword=Flow Cytometry en-keyword=ADR-Resistant Cells kn-keyword=ADR-Resistant Cells en-keyword=DIDS kn-keyword=DIDS END start-ver=1.4 cd-journal=joma no-vol=6 cd-vols= no-issue= article-no= start-page=1 end-page=5 dt-received= dt-revised= dt-accepted= dt-pub-year=1996 dt-pub=19960229 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Measurement of intracellular pH by flow cytometry using pH sensitive fluorescence dye, and influence of hyperthermia and amiloride derivatives on the intracellular pH kn-title=蛍光pH指示薬を用いたフローサイトメトリーによる細胞内pHの測定と温熱およびアミロライド誘導体の細胞内pHへの影響 en-subtitle= kn-subtitle= en-abstract=We examined relationship between intensity of intracellular fluorescence of [2', 7'-bis-(2'-carboxyethyl) carboxyfluorescein] (BCECF) and intracellular pH in Ehrlich ascites tumor cells and their adriamycin-resistant strain, and found a good correlation between them at both strains. This suggests that changes in the intracellular pH on these strains may be obtained through measurement of intracellular fluorescence of BCECF by flow cytometry. Further, we examined influence of hyperthermia, 3, 5-diamino-6-chloro-N-(diaminomethylene)pyrazinecarboxamide (amiloride), an inhibitor of Na(+)/H(+) exchanger, and its derivative; N-amidino-3-amino-6-chloro-5-(N-ethylisopropylamino) pyrazinecarboxyamide (MH-12-43) on the intracellular pH in Ehrlich ascites tumor cells. The treatment of 0.5mM amiloride or 0.05mM MH-12-43 reduced intracellular pH at 37℃, while the more reduction was observed by the treatment at 42℃. The reduction of intracellular pH by 0.05mM MH-12-43 was more substantial than that of 0.5mM amiloride at 42℃. kn-abstract=エールリッヒ腹水癌細胞とそのアドリアマイシン耐性細胞において蛍光pH指示薬2'、7'-bis-(2-carboxyethyl) carboxyfluorescein] (BCECF) の蛍光量をフローサイトメトリーで測定することによって細胞内pHの検量曲線を作成することができた。このことより、これらの細胞においてBCECFの蛍光量で細胞内pHの変化を簡易に比較できることを示唆した。さらに、温熱、Na(+)/H(+) exchanger の阻害例であるアミロライド[3,5-diamino-6-chloro-N-(diaminomethylene) pyrazinecarboxamide]、およびアミロライド誘導隊MH-12-43[N-amidino-3-amino-6-chloro-5-(N-ethyliso-propylamino) pyrazinecarboxyamide] の細胞内pHへの影響をエールリッヒ腹水癌細胞で観察した。37℃では、0.5mMアミロライド、0.05mM MH-12-43により細胞内pHは減少し、42℃処理によりさらに減少した。42℃において、0.05mM MH-12-43による細胞内pHの減少は、0.5mMアミロライドによる減少より大きかった。 en-copyright= kn-copyright= en-aut-name=AsaumiJun-ichi en-aut-sei=Asaumi en-aut-mei=Jun-ichi kn-aut-name=浅海淳一 kn-aut-sei=浅海 kn-aut-mei=淳一 aut-affil-num=1 ORCID= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name=川崎祥二 kn-aut-sei=川崎 kn-aut-mei=祥二 aut-affil-num=2 ORCID= en-aut-name=KurodaMasahiro en-aut-sei=Kuroda en-aut-mei=Masahiro kn-aut-name=黒田昌宏 kn-aut-sei=黒田 kn-aut-mei=昌宏 aut-affil-num=3 ORCID= en-aut-name=TakedaYoshihiro en-aut-sei=Takeda en-aut-mei=Yoshihiro kn-aut-name=竹田芳弘 kn-aut-sei=竹田 kn-aut-mei=芳弘 aut-affil-num=4 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name=平木祥夫 kn-aut-sei=平木 kn-aut-mei=祥夫 aut-affil-num=5 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=2 en-affil= kn-affil=岡山大学医療技術短期大学部診療放射線技術学科 affil-num=3 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=4 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=5 en-affil= kn-affil=岡山大学医学部放射線医学教室 en-keyword=BCECF kn-keyword=BCECF en-keyword=細胞内pH (Intracellular pH) kn-keyword=細胞内pH (Intracellular pH) en-keyword=フローサイトメトリー (Flow Cytometry) kn-keyword=フローサイトメトリー (Flow Cytometry) en-keyword=アミロライド (Amiloride) kn-keyword=アミロライド (Amiloride) en-keyword=MH-12-43 kn-keyword=MH-12-43 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1995 dt-pub=19950630 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=細胞外pH変化に伴う adriamycin の細胞内蓄積量に対する hyperthemia および cepharanthin の効果 kn-title=Effects of hyperthermia and cepharanthin on adriamycin accumulation with changes in extracellular pH en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=浅海淳一 kn-aut-sei=浅海 kn-aut-mei=淳一 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END